In the LEADERSNET interview, Martin Munte, CEO of Vaccentis, talks about innovations of his biopharmaceutical company, how the "VCC-001 vaccine" wants to revolutionize the fight against cancer and when it could be approved in the EU and the USA.
"Ganz generell könnte die Impfung auch bei anderen Tumoren angewendet werden" » Leadersnet
Image: Dr. Matthias Oertle, President of the board, Martin Munte, CEO, Dr. Ingrid Rauter, Head of R&D and CMO
